AUTHORS
Rachel Choi, BS, Alex Pendergast, BS2, Justin J Yoo, M.D.3, Ryan Zenhausern,, BS, PhD4, Zachary Kostamo, BS5, James Dahlman,, PhD6, Vivien A Sheehan, MD,PhD7
AFFILIATIONS
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 Georgia Institute of Technology and Emory University School of Medicine, Atlanta, Georgia, United States
5 Emory University School of Medicine, Atlanta, Georgia, United States
6 Georgia Institute of Technology and Emory University School of Medicine, Atlanta, Georgia, United States
7 Emory University School of Medicine, Atlanta, Georgia, United States
ABSTRACT
Introduction: Ex vivo gene therapy strategies for sickle cell disease (SCD) have challenges, including insufficient mobilization, genotoxic conditioning, and high cost. In vivo gene therapy can directly deliver gene editors to the hemopoietic stem cells (HSCs) in the bone marrow (BM), removing such processes. Lipid nanoparticles (LNP) are an appealing delivery vehicle for their large capacity and ability to target specific organs. LNPs have the potential to be inflammatory, which could be deleterious to SCD patients who already have high systemic inflammation from chronic hemolysis. Here we investigate the inflammatory response to LNP78 in the Townes SCD mouse model.
Methods: HbAA (M, 30 wks, n=7) and HbSS mice (M, 30 wks, n=5) were injected in the lateral tail vein with 1 mg/kg of LNP78 carrying aVHH reporter mRNA (HbAA n=4, HbSS n=2) or saline control (HbAA n=3, HbSS n=3). 6 hours after injection, mice were euthanized and blood, bones, liver, and spleen were isolated. Proinflammatory cytokines and liver enzymes (ALT, AST) were measured from plasma. Delivery to hematopoietic stem cell (HSC) populations in the BM, as well as liver and spleen were evaluated with flow cytometry using antibody to aVHH. Presence of infiltrating monocyte-derived macrophages was evaluated using flow cytometry. Data is reported as medians and analyzed using Dunn’s test.
Results: All untreated mice had comparable AST levels (496.5 U/L (HbAA) vs 406 U/L (HbSS), ns), HbAA mice had lower ALT levels (31.5 U/L (HbAA) vs 73 U/L (HbSS), ns). In HbAA mice, ALT levels modestly increased with LNP78 injection. LNP78 administration increased AST 3x and ALT levels 10x in HbSS mice compared to untreated (AST 1223.5 U/L, ALT 740 U/L). All mice treated with LNP78 experienced an increase in inflammatory cytokines IL-6 (27.9 pg/mL (HbAA) vs 112.1 pg/mL (HbAA+LNP78), ns; 19.9 pg/mL (HbSS) vs 91.5 pg/mL (HbSS+LNP78), ns), TNF-α (5.18 pg/mL (HbAA) vs 18.6 pg/mL (HbAA+LNP78), ns; 8.42 pg/mL (HbSS) vs 11.8 pg/mL (HbSS+LNP78), ns), and IL-1β (0.773 pg/mL (HbAA) vs 1.84 pg/mL (HbAA+LNP78), ns; 0.339 pg/mL (HbSS) vs 0.966 pg/mL (HbSS+LNP78), ns). Anti-inflammatory cytokine IL-10 was higher at baseline in HbSS mice and was also elevated in LNP78 treated mice (5.50 pg/mL (HbAA) vs 13.9 pg/mL (HbAA+LNP78), ns; 10.9 pg/mL (HbSS) vs 19.7 pg/mL (HbSS+LNP78), ns). Infiltrating monocyte-derived macrophages (CD11bhi F4/80int cells as a percentage of total CD45+ cells) increased in the livers of HbAA and HbSS mice treated with LNP78; HbSS mice had a higher baseline level of monocytes (11.2% (HbAA) vs 30.7% (HbAA+LNP78), p = 0.04; 14.2% (HbSS) vs 23.8% (HbSS + LNP78), ns). No change in infiltrating monocyte-derived macrophages was observed in the spleen or BM in any mice after LNP. At 6 hours after injection, LNP78 delivery to lineage negative, LSK (Lin-Sca+c-Kit+), and LT-HSC (LSK CD34- FLT3-) populations in the BM was comparable between HbAA and HbSS mice (Lin- cells 6.64% (HbAA+LNP78) vs 5.01% (HbSS+LNP78), ns; LSK 26.6% vs 15.7%; LT-HSC 17.1% vs 15.2%).
Discussion: LNP78 triggers the innate immune response 6 hours post injection at a dose of 1 mg/kg in the Townes mouse model. Despite a higher baseline level of inflammatory cytokines, HbSS mice treated with LNP78 exhibited less elevation of IL-6, TNF-α, and IL-1β compared to HbAA, suggesting a tolerance to inflammatory insult, also supported by higher baseline level of anti-inflammatory cytokine IL-10. HbSS mice, however, exhibited a higher susceptibility to liver damage. Both a higher baseline presence of AST and ALT, and a greater elevation in such enzymes after LNP administration than in HbAA mice, indicates that a lesser increase in cytokines may still cause liver damage. Further, higher baseline number infiltrating monocyte-derived macrophages was observed in the livers of HbSS mice. In total, these data suggest that despite a dampened innate immune response in HbSS mice, LNP may still have the potential to induce organ injury. However, this study only includes one timepoint; such a response may be transitory and normalize at a later timepoint. Additionally, aged mice, which typically have higher baseline levels of inflammation than younger animals, were used in this study. Younger HbSS mice may not demonstrate an inflammatory tolerance to LNP78, or as much liver damage. Future studies will probe a greater range of time points to capture a more complete picture of the innate immune response.
DISCLOSURES
Rachel Choi, BS: No relevant conflicts of interest to declare.